# NCT06564324 (NCT06564324)

> A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06564324
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Nuvation Bio Inc.
- Conditions: Non Small Cell Lung Cancer
- Interventions: Taletrectinib; Crizotinib
- Enrollment: 194
- Primary outcome: PFS (Assessed by BIRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06564324